Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Lannett Company, Inc. (LCI - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in LCI.
A key reason for this move has been the negative trend in earnings estimates revisions. For the full year, we have seen two estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $2.4 a share a month ago to its current level of $2.09.
Also, for the current quarter, Lannett has seen one downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to 40 cents a share from 56 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 10.3% in the past month.
Lannett Co Inc Price and Consensus
So, it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long-time horizon to wait.
If you are still interested in the Medical - Drug industry, you may instead consider a better-ranked stock - BioSpecifics Technologies Corp. (BSTC - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.